drugset / Trial / NCT02138812
Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel
NaSingle-groupOpen-labelTreatment
Summary
Determine the safety, tolerability, maximum tolerated dose (MTD), and recommended Phase II dose (RP2D) of BAY1161909 in combination with paclitaxel in subjects with advanced malignancies.
Timeline
- Start
- 2014-05-09
- Primary completion
- 2017-04-28
- Completion
- 2017-10-02
Outcome
Outcome not reported
Stopped (Business): “As another Mps1 inhibitor was being developed in parallel, the strategic decision was to move forward with the development of the follow up compound only.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BAY1161909 | Small molecule | 0.75 mg | — |
| Subject | BAY1161909 | Small molecule | 6 mg | — |
| Subject | Paclitaxel | Small molecule | 75 mg/m2 | Intravenous |
| Subject | Paclitaxel | Small molecule | 90 mg/m2 | Intravenous |
Indications
No indication recorded.